About Leuprolide
Continuous GnRH receptor stimulation causes receptor desensitization and downregulation. This suppresses LH/FSH → testosterone/estrogen to castrate levels. Short-term pulsatile use can transiently stimulate the axis before suppression occurs.
Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) designed as a superagonist of the gonadotropin-releasing hormone receptor; paradoxically, its continuous non-pulsatile receptor occupation produces profound hypogonadotropism by causing receptor downregulation and pituitary desensitization — the opposite effect of endogenous pulsatile GnRH release — resulting in medical castration levels of sex steroids. Continuous LHRH receptor agonism initially produces a testosterone or estrogen flare before pituitary downregulation suppresses LH and FSH secretion, reducing testosterone to castrate levels in men and estrogen to postmenopausal levels in women within 2–4 weeks; this chemical hypogonadism forms the basis for its use across hormone-sensitive conditions including prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. A landmark randomized controlled trial published in the New England Journal of Medicine compared leuprolide against diethylstilbestrol for metastatic prostate cancer and demonstrated equivalent efficacy with a markedly superior cardiovascular side-effect profile, establishing the pivotal evidence base that led to FDA approval and positioned GnRH agonists as the preferred hormonal therapy for prostate cancer. Leuprolide (Lupron, AbbVie; and generic formulations) is FDA-approved and requires a prescription; approved indications include advanced prostate cancer, endometriosis, uterine fibroids, central precocious puberty, and other hormone-sensitive conditions; it is available as daily subcutaneous injection, monthly depot, and multi-month depot formulations.
Leuprolide Benefits & Research Areas
Regulatory & Evidence
Risk Profile
Higher risk profile in research contexts. Review all contraindications carefully. Not suitable for self-administration without professional oversight.
Regulatory Status
- Availability Status
- Prescription
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Research Sources
6 sources cited · 1 strong · 4 moderate · 1 weak
1 RCT · 4 Cohorts · 1 Case series
Leuprolide versus diethylstilbestrol for metastatic prostate cancer
New England Journal of Medicine · 1984
In the landmark phase 3 randomized controlled trial of 199 patients, leuprolide (1 mg/day subcutaneous) achieved 86% objective response (equivalent to DES 85%) in previously untreated metastatic prostate cancer, with comparable testosterone and acid phosphatase suppression but significantly fewer adverse events (gynecomastia, nausea, edema, thromboembolism) than diethylstilbestrol, establishing GnRH agonism as the preferred androgen deprivation strategy.
Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system.
Int Urol Nephrol · 2026
# Summary Research found that leuprolide was associated with interstitial lung disease (ILD) reports, particularly in female patients being treated for breast cancer, as identified through analysis of FDA adverse event reports from 2003–2024. This study demonstrated that among antiandrogen agents analyzed, leuprolide contributed to female-predominant ILD cases, though the signal was not uniquely identified as novel compared to other agents in the drug class.
Terazosin as a Non-Hormonal Treatment for Endometriosis.
Int J Mol Sci · 2026
# Summary Research found that terazosin, a non-hormonal medication, reduced multiple inflammatory markers and oxidative stress in endometriotic lesions in a rat model with effectiveness comparable to leuprolide, a standard hormonal treatment. This study demonstrated that terazosin achieved these anti-inflammatory and anti-angiogenic effects without hormonal suppression, suggesting potential as an alternative therapeutic approach that warrants further clinical investigation.
Show 3 more sources ↓
Surpassing genetic height potential at final adult height after monthly depot leuprolide therapy in Taiwanese girls with central precocious or early puberty: a ROC-based analysis.
Front Pediatr · 2026
# Research Summary Research found that leuprolide therapy in Taiwanese girls with central precocious puberty enabled approximately half of the treated patients to achieve final adult heights exceeding their genetically predicted mid-parental height, with those starting treatment earlier and showing greater bone age advancement demonstrating the most favorable outcomes. This study demonstrated that while leuprolide therapy supports improved height outcomes in select patients, individualized assessment based on skeletal maturity and growth patterns during treatment is essential for prognostic evaluation.
Utility of a 40-minute LH level after depot leuprolide for diagnosis and treatment monitoring in girls with CPP.
J Endocrinol Invest · 2026
# Summary Research found that measuring luteinizing hormone (LH) levels 40 minutes after leuprolide injection provides comparable diagnostic accuracy to the standard GnRH stimulation test for assessing gonadotropic activation in girls with central precocious puberty. This study demonstrated that the post-leuprolide LH measurement could serve as a practical alternative for both initial diagnosis and treatment monitoring in settings where GnRH testing is unavailable.
Failure of a LHRH agonist in metastatic prostate cancer: a case report and review of literature.
Cancer Chemother Pharmacol · 2026
# Research Summary Research found that a patient with metastatic prostate cancer demonstrated unusual resistance to leuprolide (an LHRH agonist), with testosterone levels failing to decrease and instead progressively rising over five months despite proper administration and adherence. This study demonstrated that switching to an alternative hormonal agent (LHRH antagonist degarelix) successfully achieved testosterone suppression, highlighting the rare possibility of primary LHRH agonist resistance and the importance of monitoring testosterone levels during androgen deprivation therapy.
Leuprolide Side Effects & Safety Considerations
Higher risk profile in research contexts. Professional oversight recommended.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Buy Leuprolide — Providers & Availability
2 providersClinics
1 providerStay updated on verified Leuprolide providers
New verified providers added weekly — delivered to your inbox.
Questions to Ask Your Provider
Frequently Asked Questions — Leuprolide
Leuprolide (leuprorelin; Lupron) is a synthetic nonapeptide GnRH agonist (D-Leu6, des-Gly10-GnRH ethylamide) designed as a superagonist of the gonadotropin-releasing hormone receptor; paradoxically, its continuous non-pulsatile receptor occupation produces profound hypogonadotropism by causing receptor downregulation and pituitary desensitization — the opposite effect of endogenous pulsatile GnRH release — resulting in medical castration levels of sex steroids. Continuous LHRH receptor agonism initially produces a testosterone or estrogen flare before pituitary downregulation suppresses LH and FSH secretion, reducing testosterone to castrate levels in men and estrogen to postmenopausal levels in women within 2–4 weeks; this chemical hypogonadism forms the basis for its use across hormone-sensitive conditions including prostate cancer, endometriosis, uterine fibroids, and central precocious puberty.
HPG axis modulation, testosterone suppression, hormonal restart, GnRH axis control.
Research on Leuprolide primarily documents effects related to HPG axis modulation and testosterone suppression and hormonal restart and GnRH axis control. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.
Reported contraindications and considerations for Leuprolide include active cancer history, cardiovascular condition, thyroid condition. 1 additional consideration are noted in the safety profile above. This is educational information only — consult a qualified healthcare professional before use.
2 providers in the directory currently offer Leuprolide.
In the landmark phase 3 randomized controlled trial of 199 patients, leuprolide (1 mg/day subcutaneous) achieved 86% objective response (equivalent to DES 85%) in previously untreated metastatic prostate cancer, with comparable testosterone and acid phosphatase suppression but significantly fewer adverse events (gynecomastia, nausea, edema, thromboembolism) than diethylstilbestrol, establishing GnRH agonism as the preferred androgen deprivation strategy.